SEOUL, South Korea--(BUSINESS WIRE)--South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years. An agreement between the two parties was signed on February 22.
